title: Re-LY trial: new sub-analyses highlight stroke reduction in all types of non-valvular atrial fibrillation.
mesh_terms: D000925:Anticoagulants / Q000627:therapeutic use; D058833:Antithrombin Proteins; D001281:Atrial Fibrillation / Q000188:drug therapy*; D001562:Benzimidazoles / Q000008:administration & dosage*; D000069604:Dabigatran; D006801:Humans; D011725:Pyridines / Q000008:administration & dosage*; D016032:Randomized Controlled Trials as Topic; D018570:Risk Assessment; D020521:Stroke / Q000517:prevention & control*; D014859:Warfarin / Q000627:therapeutic use
chemical_list: D000925:Anticoagulants; D058833:Antithrombin Proteins; D001562:Benzimidazoles; D011725:Pyridines; D014859:Warfarin; D000069604:Dabigatran